GENB (Generate Biomedicines) Stock Based Compensation: $20.58 Mil (TTM As of Dec. 2025)


GENB Generate Biomedicines Inc GENB
6 GF Score
Price $16.92
! 2 Warning Signs
View Full Analysis

What is Generate Biomedicines Stock Based Compensation?

Generate Biomedicines GENB +2.18% 6 Stock Based Compensation is $20.58 Mil as of Dec. 2025. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 2 warning signs investors should review.

Generate Biomedicines's Stock Based Compensation for the six months ended in Dec. 2025 was $20.58 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was $20.58 Mil.

Generate Biomedicines Stock Based Compensation Related Terms

Generate Biomedicines Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Generate Biomedicines's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Generate Biomedicines Stock Based Compensation Chart

Generate Biomedicines Annual Data
Trend Dec24 Dec25
Stock Based Compensation
19.47 20.58

Generate Biomedicines Semi-Annual Data
Dec24 Dec25
Stock Based Compensation 19.47 20.58
GENB
6GF Score
Generate Biomedicines Inc GENB
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Generate Biomedicines Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was $20.58 Mil.

What does a Stock Based Compensation of $20.58 Mil mean?
Generate Biomedicines (GENB) has a Stock Based Compensation of $20.58 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Generate Biomedicines and its competitors.
Is Generate Biomedicines' Stock Based Compensation too high?
Generate Biomedicines' current Stock Based Compensation is $20.58 Mil. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' Stock Based Compensation compare to PVLA and SLBT?
Generate Biomedicines' Stock Based Compensation of $20.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Generate Biomedicines and its competitors. Generate Biomedicines's current Stock Based Compensation is $20.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current Stock Based Compensation of $20.58 Mil. The current Stock Based Compensation is $20.58 Mil. Generate Biomedicines' overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current Stock Based Compensation is $20.58 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Generate Biomedicines Business Description

Address 101 South Street, Suite 900, Somerville, MA, USA, 02143
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score

Get the complete analysis for GENB

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.92
Price